之江生物：累计回购约101万股

Group 1 - The core point of the article is that Zhijiang Biotech has announced a share buyback plan, repurchasing approximately 1.01 million shares, which represents 0.53% of its total share capital of about 192 million shares, with a total expenditure of approximately 22.37 million RMB [1] - The share buyback was conducted through the Shanghai Stock Exchange trading system, with the highest transaction price being 22.86 RMB per share and the lowest at 21.52 RMB per share [1] - For the year 2024, Zhijiang Biotech's revenue composition is heavily weighted towards the in vitro diagnostics industry, accounting for 98.25% of total revenue, while other businesses contribute only 1.75% [1] Group 2 - As of the report, Zhijiang Biotech has a market capitalization of 4.1 billion RMB [2]